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doi:10.1016/j.ejvs.2010.04.006Abstract Objectives: The aim of this study is to compare efficacy, early postoperative
morbidity and patient comfort of two laser wavelengths and fibre types in treatment of great
saphenous vein (GSV) incompetence resulting in varicosities of the lower limb.
Design: Prospective randomised clinical trial.
Materials and Methods: Sixty patients (106 limbs) were randomised into two groups. They were
treated with bare-tip fibres and a 980 nm laser in group 1 and radial fibres and 1470 nm laser in
group 2 in order to ablate the GSV. Local pain, ecchymosis, induration and paraesthesia in
treated regions, distance from skin, vein diameter, treated vein length, tumescent anaesthesia
volume, delivered energy and patient satisfaction were recorded. Follow-up visits were
planned on the 2nd postoperative day, 7th day, 1st, 2nd, 3rd and 6th months.
Results: Mean GSV diameters at saphenofemoral junction and knee levels were 12.1 S.D.
4.3 mm and 8.2 S.D. 2.4 mm, and 11.8 S.D. 4.1 mm and 7.9 S.D. 2.6 mm respectively in groups
1 and 2. There were 14 patients with induration, 13 with ecchymosis and nine minimal paraes-
thesia in group 1 and no or minimal local pain, minimum ecchymosis or induration in group 2.
Duration of pain and need for analgesia was also lower in group 2 (p < 0.05). There was signif-
icant difference on postoperative day 2, day 7 and 1st month control in favour of group 2 in
venous clinical severity scores (VCSS).
Conclusion: Treatment of the GSV by endovenous laser ablation using a 1470 nm laser and
a radial fibre resulted in less postoperative pain and better VCSS scores in the first month than
treatment with a 980 nm laser and a bare-tip fibre.
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1470 nm versus 980 nm for EVLA 255Varicose veins are a common disorder and occurs in about
40% of men and 32% of women.1 The effect of venous
insufficiency on patients’ quality of life is comparable with
other common chronic diseases such as arthritis, diabetes
and cardiovascular disease.2
Traditional treatment of great saphenous vein (GSV)
varicosities includes ligation of the saphenofemoral junc-
tion (SFJ) combined with GSV stripping. However, the
associated morbidity and patient dissatisfaction associated
with this treatment have led to the development of alter-
native techniques.3 Endovenous treatment modalities
(laser ablation, radiofrequency ablation and foam scle-
rotherapy) have been readily accepted by both patients
and doctors. Puglisi4 first described endovenous laser
ablation of the GSV in 1989 and the first successful results
were reported by Navarro5 in 2001. Many studies have been
published subsequently concerning this treatment. Semi-
conductor (diode) lasers have been the main laser type
employed for this treatment, although some reports have
mentioned the neodymium: yttrium-aluminium-garnet (Nd:
YAG) laser. Laser wavelengths reported include 810 nm,
940 nm, 980 nm, 1064 nm, 1320 nm and 1470 nm.3,6
However, the most appropriate wavelength is still the
subject of debate.
There is no scientific evidence that wavelength has any
effect on long-term outcome, although short-term differ-
ences have been found for some side effects.7 Clinical trial
experience with diode lasers has produced extremely low
rates of deep vein thrombosis (DVT) and paraesthesia, a low
risk of skin burns and no documented cases of pulmonary
embolism; both paraesthesia and skin burns have been
associated with 1064 nm laser treatment. The most common
side effects seen with all laser types are bruising, localised
pain, induration and discomfort along the treated vein and
superficial phlebitis.8 Results after endovenous laser abla-
tion (EVLA) with 1320 nm laser light showed good occlusion
rates, and less bruising and pain. Longer wavelengths
(>1000 nm) show greater water absorption but are overall
less strongly absorbed in blood than shorter wavelengths and
may have some advantages for endovenous laser
ablation.9e11 The 1470nmdiode laser operates at a relatively
new wavelength for this treatment and has been in use since
2006. The first successful results have been published by
Pannier et al.6 However no published data have compared
this laser wavelength with other commonly used wave-
lengths. There has also been progress in the field of laser
fibres. Recently, new fibre tips (jacket-tip fibres, glass,
metal, ceramic, diffusion and radial) were developed.12,13
The aim of the current prospective study was to
compare the efficacy, early postoperative morbidity,
patient comfort and effects on venous clinical severity
score (VCSS) of two different laser wavelengths (1470 nm
and 980 nm diode lasers) and fibres (bare-tip fibre and
radial fibres) in the treatment of GSV reflux.
Methods
Patients
The study was approved by our institutional ethics committee
and an informed written consent was obtained from patients.Between October 2008 and February 2009, 71 patients pre-
senting with symptomatic varicose veins were considered for
inclusion in the study which was undertaken at Gulhane Mili-
tary Academy of Medicine Department of Cardiovascular
Surgery. All patientswereexamined clinically andwith duplex
ultrasound (US) imaging using a LOGIC Book XP (GE Health-
care, Buckinghamshire, UK) system to assess the deep and
superficial veins of both lower limbs to allow the Clinical
Etiological Anatomical Pathological (CEAP)14 classification to
be assessed for each patient. Venous clinical severity scores
(VCSS) were recorded. Duplex examination was performed
with patients in the upright position. Reflux was defined as
retrograde flow with a duration of 0.5 s or greater duration
after a Valsalvamanoeuvre, in the proximal part of the vein or
manual compression and decompression of the calf to assess
the distal part of the vein. The diameter of the GSV was
measured at the level of the SFJ and at the knee, the distance
of the GSV from skin was also measured.
Patients with a history of previous DVT, concomitant
peripheral arterial disease (ABPI < 0.8), difficulty in
ambulation, pregnant or breast-feeding, recurrent varicose
veins and those who had reflux in other axial veins, (ante-
rior accessory great saphenous vein, small saphenous vein)
or perforators were excluded from the study. Patient
progress through this study is shown in a CONSORT diagram
(Fig. 1).
Eleven patients were excluded from the study. Of these,
two were pregnant, three had a history of previous DVT, one
had additional peripheral arterial disease, three had addi-
tional reflux in other venous segments detailed ahead and
two declined to undergo the randomisation process (these
two patients were treated with the 1470 nm laser). The
remaining 60 patients (106 limbs) were randomised into two
groups according to a computer-generated randomisation
list. Group 1 (nZ 30)was treatedwith the 980 nmdiode laser
(Biolitec AG, Germany) and bare-tip laser fibre (ElvesPlus,
BiolitecAG,Germany).Group 2 (nZ 30)was treatedwith the
1470 nm diode laser (Biolitec AG, Germany) and radial laser
fibre (Elves radial, Bolitec AG, Bonn, Germany).
Primary outcomes of the study were to compare early
postoperative morbidity assessed by the extent of ecchy-
mosis, paraesthesia, postoperative pain, induration and
VCSS scores. Secondary outcome measures were patient
satisfaction and comfort related with both procedures.
EVLA procedure
All patients underwent the EVLA procedure under intrave-
nous midazolam sedation with oxygen supplementation. All
GSVs were cannulated percutaneously with a 16-gauge nee-
dle under US control at the knee level with the patient in
a reverse Trendelenburg position tomaximise vein diameter.
Then a guide-wire inserted through the needle and a 6-F
introducer sheath (INPUT Intraducer sheath, Medronic
Ireland Parkmore Business Park West, Galway, Ireland) was
placedover the guide-wire into theGSV in group2. In group1,
a long guide-wire was inserted through the needle and a long
sheath positioned over the guide-wire 2 cm below the SFJ. A
bare-tip 600-mm-diameter laser fibre was inserted into the
long sheath and locked. In group 2, a radial catheter was
directly inserted through the sheath. In both groups, the tip
of the laser fibre was positioned 1e2 cm below the SFJ under
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Figure 1 Consort flow diagram of the study.
256 S. Doganci, U. DemirkilicUS guidance and confirmed by direct visualisation of the red
aiming beam through the skin. Perivenous tumescent local
anaesthesia (TLA) (1000 ml saline 0.9%, 50 ml lidocaine 2%,
1ml Epinenephrine 1:1000, 10mEq NaHCO3) was given under
US control. Laser energy was applied using the laser’s
continuous mode and a constant pullback with a rate corre-
sponding to 90 J cm1 linear endovenous energy density
(LEED). In both groups, laser powerwas set to 15Wpower and
total laser energy was recorded. After removing the fibre,
closure of the GSV was confirmed by US. Concomitant phle-
bectomies were performed in both groups and a compression
bandage was applied over the course of the treated vein for
24 h. Patients then wore graduated compression stockings
(20e30 mmHg, knee-high) continuously during the following
7 days. After the first week, they continued towear stockings
during the day. Prophylactic low-molecular-weight heparin
was not used in either group. Patients were advised to walk
regularly during recovery from treatment and diclofenac
75 mg twice daily as required was prescribed for analgesia.
Follow-up
Patients were re-examined on the 2nd and 7th post-
operative day, and at months 1, 2, 3 and 6 after the
procedure. Clinical examination and duplex US were
undertaken to assess efficacy of treatment including
ultrasound assessment of the GSV to detect patent or
incompetent veins. VCSS, postoperative pain, patient
satisfaction, side effects, adverse events and recurrence
rates were evaluated and recorded at each visit.
Patient satisfaction was assessed on a scale ranging from
0 to 4. The questions were ‘Are you satisfied with themethod being used?’ (0 Z very satisfied; 1 Z satisfied;
2 Z fairly satisfied; 3 Z not satisfied; 4 Z extremely
unsatisfied) and ‘would you choose endovenous laser
therapy again?’ (0 Z definitely; 1 Z probably; 2 Z don’t
know; 3 Z probably not; 4 Z definitely not).
Local pain, duration of pain, duration of requirement for
analgesia, return to daily activities, ecchymosis, skin burn,
skin necrosis, induration and paraesthesia over treated
parts of legs were also recorded at postoperative follow-up
visits. These parameters were recorded in a written form by
the patients during the follow-up visits. Ecchymosis and
paraesthesia were recorded in regions of the limb adjacent
to the ablated vein segments. The areas of ecchymosis and
paraesthesia were not measured. These outcome measures
were recorded as present or absent.
Statistical analysis
Recurrence, postoperative complications, morbidity and
side-effect rates were compared between groups using
Fisher’s exact test. Patient satisfaction in the two groups
was compared using a ManneWhitney U test. A p value of
<0.05 was considered significant. All analyses were per-
formed using the statistical package SPSS for Windows
version 15.0 (SPSS, Chicago, IL, USA).
Results
Successful percutaneous access and endovenous placement
of the laser fibre were achieved in all patients and were
well tolerated. A total of 52 limbs of 30 patients in group 1
Table 1 Preoperative patient demographics.
Parameters Group 1 (N Z 30) 980 nm Bare-tip fibre Group 2 (N Z 30) 1470 nm Radial fibre
Number of treated legs 52 54
Gender (M/F) 16/14 19/11
Mean age (years) 35 S.D. 9.2 36 S.D. 7.6
Mean GSV diameter (mm)
SFJ level 12.1 S.D. 4.3 11.8 S.D. 4.1
Knee level 8.2 S.D. 2.4 7.9 S.D. 2.6
Mean reflux duration at SFJ (s) 6.5 S.D. 1.7 6.8 S.D. 1.3
GSV distance from the skin (cm) 3.7 S.D. 1.8 3.4 S.D. 1.9
CEAP classification/limb
C2 16 16
C3 29 30
C4 7 8
Ep 52 54
M: Male, F: Female, GSV: Great saphenous vein, SFJ: Saphenofemoral junction.
1470 nm versus 980 nm for EVLA 257and 54 limbs of 30 patients in group 2 were treated.
Demographic details and results of preoperative clinical
and US examinations are shown in Table 1. The two groups
of patients are very similar.
Operative data are shown in Table 2. Our aim was to
achieve a LEED of 90 J cm1 and this appears to have been
achieved in both groups. Similar amounts of TLA were used
in both groups and the volume was approximately 10 ml per
treated centimetre, which we consider to be optimum in
minimising postoperative ecchymosis and paraesthesia.
No patient was lost from this series during the 6-month
follow-up period. No evidence of residual flow or venous
reflux was found on US imaging at any time during follow-up.
VCSS scores improved significantly in both groups at each
follow-up visit (Table 3). However improvements of VCSS for
the second day, seventh day and the first month were
significantly better in group 2 than in group 1. After the first
month, there was no difference at the recorded parameters.
Table 4 summarises the side effects and other assess-
ments of the outcome of this clinical trial. Themost frequent
side effects in both groups were ecchymosis, induration and
minor paraesthesia, all of whichweremore common in group
1. Severe complications such as DVT, pulmonary embolism,
skin burns, motor nerve lesions or the formation of arterio-
venous fistula did not occur in any limb. Assessments ofTable 2 Operative data.
Parameters
Mean treated GSV length (cm)
Used laser power (W)
LEED (J/cm)
Mean total energy/limb (J)
Mean TLA volume/limb (ml)
Mean procedure duration/limb (min) (EVLA þ Miniphlebectomy)
Number of phlebectomies/limb
Immediate postoperative closure rate (%)
GSV: Great saphenous vein, W: Watt, LEED: Linear endovenous
EVLA: Endovenous laser ablation.postoperative pain included duration of pain and need for
analgesia, both of which were less in group 1 patients.
Ecchymosis was also less frequently seen in patients from
group 2. However, in those patients in whom ecchymosis
developed, the mean duration was almost 2 weeks in both
groups. Subcutaneous induration along the treated veins
after EVLA resembling either a palpable cord or the feeling of
a shortened muscle at the medial part of the thigh were
noticed in 14 limbs in group 1 and 3 limbs in group 2
(p< 0.001). This lasted for a mean of 8 weeks in group 1 and
less than 3 weeks in group 2. Paraesthesia in the region of
treated veins was more common in group 1 but overall
symptoms were of minor severity and themean duration was
not longer than 4 weeks in both groups.
Patient satisfaction
Subjective assessment of the treatment by patients at the
sixth-month visit demonstrated that most of the patients
were very satisfied with the treatment. In group 1, 10
patients were very satisfied with the method, nine were
satisfied, nine were fairly satisfied and two were not
satisfied. The mean score for group 1 was 1.1. In group 2, 15
patients were very satisfied, 12 patients were satisfied and
three were fairly satisfied. The mean for group 2 was 0.6.Group 1 (N Z 30)
980 nm Bare-tip fibre
Group 2 (N Z 30)
1470 nm Radial fibre
39.2 S.D. 6.2 40.6 S.D. 7.1
15 15
90 90
3548 S.D. 564 3696 S.D. 642
310 S.D. 76 296 S.D. 83
35 S.D. 9.4 34 S.D. 10
5.2 S.D. 1.7 4.9 S.D. 1.5
100 100
energy density, J: Joule, TLA: Tumescent local anaesthesia,
Table 3 Changes in venous clinical severity score.
Time point Group 1 (N Z 30) 980 nm Bare-tip fibre Group 2 (N Z 30) 1470 nm Radial fibre P value
Preoperative 8.6 S.D. 3.2 8.4 S.D. 2.9 N.S.
PO second day 5.3 S.D. 2.5 4.6 S.D. 2.4 P < 0.05
PO seventh day 5.0 S.D. 2.2 4.2 S.D. 2.0 P < 0.05
PO first month 4.2 S.D. 2.1 3.7 S.D. 1.9 P < 0.05
PO second month 3.5 S.D. 1.9 3.1 S.D. 1.6 N.S.
PO third month 3.2 S.D. 1.7 2.9 S.D. 1.5 N.S.
PO sixth-month 2.2 S.D. 0.9 2.0 S.D. 0.7 N.S.
PO: postoperative.
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significant (p < 0.05).
The response to the question ‘Would you choose endo-
venous laser therapy again?’ was ‘definitely’ in eight
patients, ‘probably yes’ in nine, ‘do not know’ in nine and
‘probably would not’ in four patients in group 1. The mean
score for group 1 was 1.3. In group 2, 16 patients replied
‘definitely’, 10 ‘probably yes’, three ‘do not know’ and one
patient replied ‘probably would not’. The mean for group 2
was 0.5. The difference between the groups was statisti-
cally significant (p < 0.05).
Compression stockings were worn for similar periods in
the two patient groups. Return to daily activities was
slightly earlier in group 2 than in group 1 (Table 4).
Discussion
In recently published studies, high success rates after EVLA
have been reported.3,9,15 These have been based mainly on
duplex US assessment of the treated veins. In our study, we
found 100% ablation of veins in both treatment groups at 6Table 4 Postoperative data.
Parameters Group 1 (N Z 30) 98
Bare-tip fibre
Pain duration (day) 3.2 S.D. 4.1
Duration of analgesia need
(day)
7.1 S.D.3.9
Induration (number of limbs) 14
Ecchymosis (number of limbs) 13
Skin necrosis (number of limbs) 0
Skin burn (number of limbs) 0
Paraesthesia (number of limbs) 9
Deep vein thrombosis 0
Pulmonary Embolus 0
Return to daily activity (day) 2.3 S.D. 2.1
Duration of compression
stockings (day)
56 S.D. 17
Patient satisfaction (median) 1.1 S.D.0.95 (1)
Willing to undergo EVLA again
(median)
1.3 S.D.1.02 (1)
6th month closure rate (%) 100
EVLA: Endovenous laser ablation.
Patient satisfaction: 0 Z very satisfied; 1 Z satisfied; 2 Z fairly sati
Willing to undergo EVLA again:0 Z definitely; 1 Z probably; 2 Z domonths. Laser systems with emission wavelengths of
1320 nm and 1470 nm have their main absorption in
water10,11 but the effect of these wavelengths on the vein
wall is still under discussion. Good efficacy of a 1320 nm Nd:
Yag system with reduced post-treatment pain and bruising
compared to shorter wavelength lasers has been repor-
ted.10,16 Successful endovenous ablation using a 1470 nm
laser has been reported by Pannier et al.,6 but no study has
compared this with other commonly used laser systems.
In this prospective randomised study, we found that side
effects such as pain, induration, ecchymosis and paraes-
thesia were significantly reduced with the 1470 nm laser
and radial catheter system compared to the 980 mm bare-
tip laser fibre. Pannier6 reported phlebitic reactions in
three cases and 9.5% paraesthesia in treated legs at the six-
month follow-up in their study group. However, it is not
clear whether they used a bare-tip fibre or radial fibre. Side
effects were also more common in patients treated with
a LEED of >100 J cm1. In our study, in group 2 (1470 nm),
we experienced only a few minor complications of this
type. This may be the result of limiting the LEED to
90 J cm1 and the use of radial laser fibres.0 nm Group 2 (N Z 30)
1470 nm Radial fibre
P value
2.2 S.D.3.4 P < 0.05
5.8 S.D.2.7 P < 0.05
3 P < 0.001
2 P < 0.001
0 NS
0 NS
1 P < 0.001
0 NS
0 NS
1.6 S.D. 1.8 P < 0.05
60 S.D. 20 NS
0.6 S.D.0.67 (0.5) P < 0.05
0.5 S.D.0.8 (0) P < 0.05
100 NS
sfied; 3 Z not satisfied; 4 Z extremely unsatisfied.
n’t know; 3 Z probably not; 4 Z definitely not.
1470 nm versus 980 nm for EVLA 259In a study by Almeida et al.11 1470 nm laser and radial
fibres were used with low LEED levels (20e30 J cm1). This
was not a randomised study but the authors concluded that
in comparison to 980 nm wavelength systems (their past
experience) there was a marked reduction in postoperative
pain and ecchymosis. They attributed this finding to
reduced vein-wall perforations with this system. Our find-
ings are similar to those reported in this study with reduced
postoperative pain, although we used higher LEED levels.
The design of the fibre tip probably has a substantial
effect on the early postoperative course. Kabnick et al.
concluded that a jacket-tip laser fibre produces a more
tolerable procedure, with less ecchymosis and post-
operative pain.12 The use of radial fibres in our study almost
certainly had a large effect on the outcome.
Desmytte`re et al.17 have reported their long-term result
with a 980-nm diode laser. In this study, 500 patients were
treated. They reported 60% ecchymosis and 7% transient
paraesthesia following treatment. In our study, the
outcome in group 1 is comparable with Desmytte`re’s study,
although far fewer complications were seen in group 2.
In general, patients report high levels of satisfaction
following laser ablation of saphenous veins, according to
a number of studies. Our study confirms that patients were
satisfied with the outcome of treatment and that a high
proportion of patients would be content to undergo further
treatment using endovenous ablation. We observed higher
levels of satisfaction and agreement to undergo further
treatment in group 2 patients, consistent with our other
outcomemeasures. VCSS scores also show that during the first
postoperativemonth symptoms were fewer in group 2 than in
group 1. However, following this there was no difference.
In conclusion, 1470- and 980-nm diode lasers and both
laser fibre types are effective in the treatment of GSV
varicosities by endovenous laser ablation. However, early
postoperative patient comfort, patient satisfaction and
acceptability of the procedure are higher in 1470 nm laser
and radial fibre group which showed fewer side effects. A
limitation of this study is that we cannot identify whether
these results are attributable solely to the laser frequency,
the fibre tip or a combination of both factors.
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